Kukje Pharma Co., Ltd.
Financials
Valuation Metrics
Kukje Pharma Co., Ltd.'s Market Cap is ₩723B. At end of 2025 it was ₩910B. Ranked #1447 of 2,405 in KR market (top 60%), #625 of 778 on KOSPI (top 80%), #160 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 69%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 72.26B KRW | KR#1,447/2,405 Sec#160/231 |
| Revenue | 181.27B KRW | KR#1,082/2,405 Sec#64/231 |
| Net Income | 4.99B KRW | KR#1,212/2,405 Sec#81/231 |
| Total Assets | 185.21B KRW | KR#1,367/2,405 Sec#100/231 |
| Net Assets | 99.37B KRW | KR#1,421/2,405 Sec#112/231 |
| Employees | 256 | KR#911/2,405 Sec#78/231 |
| Value | ||
| P/E | 14.41x | KR#1,076/2,405 Sec#65/231 |
| P/B | 0.72x | KR#1,226/2,405 Sec#72/231 |
| P/S | 0.40x | KR#819/2,405 Sec#33/231 |
| EV/EBITDA | 19.52x | KR#1,033/2,405 Sec#61/231 |
| FCF Yield | 3.07% | KR#1,001/2,405 Sec#62/231 |
| Profitability | ||
| ROE | 5.02% | KR#1,093/2,405 Sec#76/231 |
| ROA | 2.70% | KR#1,091/2,405 Sec#80/231 |
| Op. Margin | 2.47% | KR#1,315/2,405 Sec#93/231 |
| Revenue Growth | 8.02% | KR#1,010/2,405 Sec#98/231 |
| Earnings Growth | -21.78% | KR#937/2,405 Sec#59/231 |
| Financial Health | ||
| Debt Ratio | 86.38% | KR#1,414/2,405 Sec#165/231 |
| Total Debt | 30.00B KRW | KR#1,226/2,405 Sec#96/231 |
| FCF | 2.22B KRW | KR#1,064/2,405 Sec#75/231 |
| Cash | 14.91B KRW | KR#1,432/2,405 Sec#112/231 |
| Current Ratio | 1.14x | KR#1,555/2,405 Sec#159/231 |
| Net Debt/EBITDA | 3.37x | KR#929/2,405 Sec#70/231 |
| Dividend | ||
| Div. Yield | 0.90% | KR#1,169/2,405 Sec#68/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -20.28% | KR#1,118/2,405 Sec#76/231 |
| 1M Return | 3.66% | KR#192/2,405 Sec#20/231 |
| From 52W High | -37.84% | KR#685/2,405 Sec#45/231 |
| 1Y MDD | -41.78% | KR#629/2,405 Sec#42/231 |
| Trading | ||
| Volume | 231,611 shares | KR#324/2,405 Sec#22/231 |
| Trading Value | 782.8M KRW | KR#657/2,405 Sec#69/231 |
| Foreign Own. | 3.70% | KR#1,114/2,405 Sec#101/231 |
| Per Share | ||
| EPS | 236 KRW | KR#1,241/2,405 Sec#85/231 |
| BPS | 4,696 KRW | KR#1,552/2,405 Sec#113/231 |
Company Info
Kukje Pharma, established in 1959, is a specialized pharmaceutical manufacturing and sales company, listed on the securities market in 1975, and founded its subsidiary Kukje Care in 2011. It handles both specialized pharmaceuticals, like QRalone Eye Drops, and over-the-counter drugs, supplying products nationwide from its Seongnam headquarters and manufacturing/research facilities in Ansan. The company is actively researching 2 new drugs and 3 modified new drugs, aiming for new drug development and increased sales by developing anti-inflammatory treatments such as indole carboxamide derivatives. Kukje Pharma is headquartered in Seongnam-si, Gyeonggi-do.